Others have reported that enriched populations of ALDH1+ cells correlate with poor clinical outcomes25,51,52, suggesting the use of ALDH1 as a prognostic biomarker for breast cancer patients. This evidence concerns the gene ALDH1A1 and breast carcinoma.